Jonathan Rothberg, AI Therapeutics founder (Stuart Ramson/AP Images for Detect, Inc.)
Private startup claims a PhIIa win in subset of ALS patients, but questions remain
A private Connecticut biotech is claiming a win from a small Phase IIa trial in ALS patients with a specific genetic mutation.
AI Therapeutics said …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
